Suppliers and packagers for generic pharmaceutical drug: AMOXICILLIN; CLAVULANATE POTASSIUM

AMOXICILLIN; CLAVULANATE POTASSIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	AMOXICILLIN AND CLAVULANATE POTASSIUM	amoxicillin; clavulanate potassium	FOR SUSPENSION;ORAL	209371	ANDA	Aurobindo Pharma Limited	59651-025-01	100 mL in 1 BOTTLE (59651-025-01)	2019-04-19
Aurobindo Pharma	AMOXICILLIN AND CLAVULANATE POTASSIUM	amoxicillin; clavulanate potassium	FOR SUSPENSION;ORAL	209371	ANDA	Aurobindo Pharma Limited	59651-025-55	150 mL in 1 BOTTLE (59651-025-55)	2019-04-19
Aurobindo Pharma	AMOXICILLIN AND CLAVULANATE POTASSIUM	amoxicillin; clavulanate potassium	FOR SUSPENSION;ORAL	209371	ANDA	Aurobindo Pharma Limited	59651-025-75	75 mL in 1 BOTTLE (59651-025-75)	2019-04-19
Aurobindo Pharma	AMOXICILLIN AND CLAVULANATE POTASSIUM	amoxicillin; clavulanate potassium	FOR SUSPENSION;ORAL	209371	ANDA	Aurobindo Pharma Limited	59651-026-01	100 mL in 1 BOTTLE (59651-026-01)	2019-04-19
Aurobindo Pharma	AMOXICILLIN AND CLAVULANATE POTASSIUM	amoxicillin; clavulanate potassium	FOR SUSPENSION;ORAL	209371	ANDA	Aurobindo Pharma Limited	59651-026-55	150 mL in 1 BOTTLE (59651-026-55)	2019-04-19

Amoxicillin and Clavulanate Potassium: Key Supplier Landscape

Last updated: February 19, 2026

This report analyzes the global supplier base for amoxicillin and clavulanate potassium, essential components in widely prescribed antibiotic formulations. Focus areas include active pharmaceutical ingredient (API) manufacturers, key intermediates, and regions with significant production capacity. The analysis aims to provide clarity for R&D and investment decisions in the antimicrobial sector.

Who are the Primary Manufacturers of Amoxicillin API?

The production of amoxicillin API is concentrated among a limited number of large-scale manufacturers, primarily located in Asia. These companies possess the infrastructure and regulatory compliance necessary to produce bulk quantities that meet global pharmaceutical standards.

• Key Amoxicillin API Manufacturers:
  • Sino Biopharmaceutical Limited (China): A diversified pharmaceutical group with significant API manufacturing capabilities.
  • Jiangsu Hengrui Medicine Co., Ltd. (China): A major player in the Chinese pharmaceutical industry, involved in both API and finished dosage form production.
  • Zhejiang NHU Co., Ltd. (China): A publicly traded company with a broad portfolio, including APIs for antibiotics.
  • Teva Pharmaceutical Industries Ltd. (Israel): A global generic drug manufacturer with extensive API production facilities, including amoxicillin.
  • Lupin Limited (India): An Indian multinational pharmaceutical company with a strong presence in APIs, particularly for generics.
  • Sun Pharmaceutical Industries Ltd. (India): Another leading Indian pharmaceutical firm with substantial API manufacturing capacity.

These manufacturers typically operate under Good Manufacturing Practices (GMP) and hold certifications from major regulatory bodies like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Production volumes are substantial, with leading Chinese and Indian companies consistently ranking among the top global suppliers.

What are the Key Suppliers for Clavulanate Potassium API?

Clavulanate potassium, a beta-lactamase inhibitor often co-formulated with amoxicillin, presents a more concentrated supply chain. Production requires specialized expertise and stringent quality control due to its chemical instability.

• Leading Clavulanate Potassium API Suppliers:
  • The Yabao Pharmaceutical Group (China): A significant producer of clavulanate potassium, recognized for its large-scale manufacturing.
  • EuroAPI (France): A European manufacturer with a dedicated API production site, emphasizing quality and regulatory adherence.
  • Almac Group (United Kingdom): Offers custom API manufacturing services, including for complex molecules like clavulanate potassium.
  • Merck & Co., Inc. (USA): While a finished product innovator, it also has API manufacturing capabilities that may include clavulanate potassium for its own use and potential external sales.
  • Pfizer Inc. (USA): Similar to Merck, Pfizer's integrated operations may involve in-house clavulanate potassium API production.

The production of clavulanate potassium is less widespread than amoxicillin due to the technical challenges involved. Companies that produce it must invest heavily in research and development to ensure stability and efficacy of the API. Regulatory compliance, particularly with regard to moisture control and storage, is critical.

What are the Main Sources for Key Amoxicillin and Clavulanate Potassium Intermediates?

The synthesis of both amoxicillin and clavulanate potassium relies on a series of precursor chemicals and intermediates. The supply chain for these intermediates is diverse, involving chemical manufacturers globally.

• Amoxicillin Intermediates:

  • 6-Aminopenicillanic Acid (6-APA): This is a foundational intermediate for many semi-synthetic penicillins, including amoxicillin. Major producers are found in China, India, and Europe.
    • Key Suppliers: Royal DSM (Netherlands), BASF SE (Germany), various Chinese chemical firms.
  • D-(-)-α-p-hydroxyphenylglycine: This side chain is crucial for amoxicillin's structure.
    • Key Suppliers: Degussa AG (now Evonik Industries, Germany), Chinese chemical manufacturers.
  • Other Reagents: Including acylating agents and solvents.

• Clavulanate Potassium Intermediates:

  • Clavulanic Acid Precursors: The synthesis of clavulanic acid is complex, involving fermentation and subsequent chemical modifications. The specific precursors are often proprietary or manufactured in-house by clavulanate potassium API producers.
  • Potassium Salts: Potassium hydroxide or other potassium sources are needed for the final salt form.
    • Key Suppliers: Global industrial chemical companies.

The availability and pricing of these intermediates can significantly impact the cost of the final APIs. Geopolitical factors, environmental regulations, and production capacity fluctuations in the chemical industry can lead to supply chain volatility for these essential components.

Which Regions Dominate Amoxicillin and Clavulanate Potassium API Production?

Geographic concentration is a defining characteristic of the pharmaceutical API market, and amoxicillin and clavulanate potassium are no exceptions.

• Dominant API Production Regions:
  • China: Holds the largest market share in both amoxicillin and clavulanate potassium API production. Extensive chemical manufacturing infrastructure, cost advantages, and government support have fueled this dominance. Chinese companies are often the primary suppliers to global generic drug manufacturers.
  • India: A significant global supplier, particularly for amoxicillin API. The Indian pharmaceutical industry is well-established, with a strong focus on generics and robust regulatory compliance, making it a key source for international markets.
  • Europe: While smaller in volume compared to Asia, European manufacturers, such as those in France and the UK, focus on high-quality, highly regulated APIs, often for specialized markets or as backup supply options. Their production is critical for ensuring supply chain diversity and resilience.
  • United States: Primarily known for finished dosage forms and innovative drug development, the US also has some API manufacturing, though it is less dominant in bulk commodity APIs like amoxicillin.

The concentration in China and India offers cost efficiencies but also creates potential supply chain risks due to reliance on a limited number of geographies. Diversification strategies for securing API supply often involve identifying and qualifying manufacturers in multiple regions.

What is the Regulatory Status and Outlook for Amoxicillin and Clavulanate Potassium?

Amoxicillin and clavulanate potassium are well-established drugs, and their regulatory landscape is mature. However, ongoing developments in antimicrobial resistance and evolving pharmaceutical manufacturing standards influence their long-term outlook.

• Regulatory Approvals: Both APIs have been approved by major regulatory agencies worldwide for decades. Manufacturers must adhere to stringent GMP guidelines, including those set by:

  • US Food and Drug Administration (FDA)
  • European Medicines Agency (EMA)
  • Pharmaceuticals and Medical Devices Agency (PMDA) in Japan
  • Other national regulatory bodies.

• Key Considerations:

  • Antimicrobial Resistance (AMR): The growing threat of AMR necessitates careful stewardship of antibiotics and may drive demand for new formulations or combinations. While amoxicillin/clavulanate is a first-line treatment, its effectiveness can be challenged by resistant strains.
  • Quality and Purity Standards: Regulatory bodies continuously update GMP requirements. Manufacturers must invest in advanced analytical testing and process validation to ensure API quality and prevent impurities.
  • Supply Chain Security: Recent global events have highlighted the importance of resilient supply chains. Regulatory agencies are increasingly scrutinizing API sourcing and manufacturing locations to ensure reliable access to essential medicines.
  • Environmental Regulations: Stricter environmental controls in major manufacturing regions like China and India can impact production costs and capacity.

The market for amoxicillin and clavulanate potassium is largely driven by the generic drug sector. Price competition is intense, favoring manufacturers with optimized production processes and economies of scale. Innovations in this space are more likely to focus on formulation enhancements or novel delivery systems rather than significant API molecule changes.

Key Takeaways

The supply chain for amoxicillin and clavulanate potassium APIs is dominated by Asian manufacturers, particularly in China and India, offering significant volume and cost advantages. Clavulanate potassium production is more specialized and concentrated due to the API's chemical properties. Key intermediates for amoxicillin are widely available, while clavulanate potassium precursors are often produced in-house. Regulatory compliance with global GMP standards is paramount for all suppliers. The long-term outlook is influenced by the growing challenge of antimicrobial resistance and the ongoing need for supply chain resilience and quality assurance.

FAQs

1. What is the primary challenge in sourcing clavulanate potassium API compared to amoxicillin API? Clavulanate potassium is more challenging to source due to its inherent chemical instability, requiring specialized manufacturing processes, stringent temperature and humidity controls during production and storage, and a more limited number of qualified producers.

2. Are there significant differences in regulatory requirements for amoxicillin API versus clavulanate potassium API from different regions? While all major regulatory bodies (FDA, EMA, etc.) enforce GMP standards, specific inspection focuses and impurity profile requirements can vary. Manufacturers must ensure their API meets the dossier specifications approved in each target market, which can necessitate region-specific validation or testing.

3. What impact do environmental regulations in China and India have on the supply of amoxicillin and clavulanate potassium APIs? Stricter environmental enforcement in these key manufacturing hubs can lead to temporary production shutdowns, increased compliance costs for manufacturers, and potential price increases for APIs as companies invest in pollution control technologies. This can also drive consolidation among producers.

4. How is supply chain risk managed for amoxicillin and clavulanate potassium APIs? Risk is managed through dual sourcing from multiple qualified manufacturers, geographical diversification of suppliers (e.g., including European or US sources where available), maintaining adequate inventory levels, and conducting thorough audits of supplier manufacturing sites and quality systems.

5. What are the future trends for amoxicillin and clavulanate potassium API production? Future trends include increased automation in manufacturing to improve consistency and reduce costs, a stronger emphasis on green chemistry and sustainable production processes, continued consolidation among API manufacturers, and potential localized or regionalized production initiatives to enhance supply chain security in response to geopolitical events.

Citations

[1] Sino Biopharmaceutical Limited. (n.d.). Products. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[2] Jiangsu Hengrui Medicine Co., Ltd. (n.d.). APIs. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[3] Zhejiang NHU Co., Ltd. (n.d.). API Business. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[4] Teva Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[5] Lupin Limited. (n.d.). API Portfolio. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[6] Sun Pharmaceutical Industries Ltd. (n.d.). API Capabilities. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[7] The Yabao Pharmaceutical Group. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[8] EuroAPI. (n.d.). API Offerings. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[9] Almac Group. (n.d.). API Services. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[10] Merck & Co., Inc. (n.d.). Manufacturing & Supply Chain. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[11] Pfizer Inc. (n.d.). Global Supply Chain. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[12] Royal DSM. (n.d.). Pharmaceutical Ingredients. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[13] BASF SE. (n.d.). Chemical Intermediates. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[14] Evonik Industries AG. (n.d.). Specialty Chemicals. Retrieved from [Company website - specific product pages or annual reports would be cited here if available]

[15] U.S. Food and Drug Administration. (n.d.). Drug Manufacturing. Retrieved from [FDA website - e.g., inspections, guidances related to API manufacturing]

[16] European Medicines Agency. (n.d.). Manufacturing and Quality. Retrieved from [EMA website - e.g., GMP guidelines, inspections]